Inactive Instrument

Press Releases Biosyent Inc. Toronto S.E.

Equities

BioSyent In-Licenses Endocrinology Product for Canada	06-12	GL
BioSyent Releases Financial Results for Q1 2024	05-16	GL
BioSyent Declares Second Quarter 2024 Dividend	05-16	GL
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024	05-09	GL
BioSyent to Attend Planet MicroCap Showcase	04-23	GL
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement	04-15	GL
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference	04-10	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	04-03	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	04-03	AQ
BioSyent to Present at LD Micro New York Investor Conference	04-01	GL
BioSyent Announces Grant of Restricted Share Units	03-27	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	03-13	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	03-13	AQ
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024	03-06	GL
BioSyent Named to 2024 TSX Venture 50	02-21	GL
BioSyent Named to 2024 TSX Venture 50	02-21	AQ
BioSyent Declares First Quarter 2024 Dividend	02-06	GL
BioSyent Declares First Quarter 2024 Dividend	02-06	AQ
BioSyent Announces Renewal of Normal Course Issuer Bid	12-13	GL
BioSyent Announces the Availability of Gelclair® in Canada	11-20	GL

No results for this search